Cell-mediated immunity to AAV vectors, evolving concepts and potential solutions

Frontiers in Immunology

Volumn 5, Issue JUL, 2014, Pages

  Basner Tschakarjan, Etiena ^a   Mingozzi, Federico ^b,c  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b SORBONNE UNIVERSITÉ   (France)

^c GÉNÉTHON   (France)

Author keywords

AAV vectors; Gene therapy; Immune modulation; Immunogenicity; T cell responses

Indexed keywords

EID: 84905658629     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00350     Document Type: Review

References (122)

1. Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science (2013) 341:1233158. doi: 10.1126/science.1233158
2. Aiuti A, Biasco L, Scaramuzza S, Ferrua F, Cicalese MP, Baricordi C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science (2013) 341:1233151. doi:10.1126/science.1233151
3. Cideciyan AV, Aleman TS, Boye SL, Schwartz SB, Kaushal S, Roman AJ, et al. Human gene therapy for RPE65 isomerase deficiency activates the retinoid cycle of vision but with slow rod kinetics. Proc Natl Acad Sci U S A (2008) 105:15112-7. doi:10.1073/pnas.0807027105
4. Aiuti A, Cattaneo F, Galimberti S, Benninghoff U, Cassani B, Callegaro L, et al. Gene therapy for immunodeficiency due to adenosine deaminase deficiency. N Engl J Med (2009) 360:447-58. doi:10.1056/NEJMoa0805817
5. Bainbridge JW, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber's congenital amaurosis. N Engl J Med (2008) 358:2231-9. doi:10.1056/NEJMoa0802268
6. Cartier N, Hacein-Bey-Abina S, Bartholomae CC, Veres G, Schmidt M, Kutschera I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 326:818-23. doi:10.1126/science.1171242
7. Cavazzana-Calvo M, Payen E, Negre O, Wang G, Hehir K, Fusil F, et al. Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia. Nature (2010) 467:318-22. doi:10.1038/nature09328
8. Maguire AM, Simonelli F, Pierce EA, Pugh EN Jr, Mingozzi F, Bennicelli J, et al. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med (2008) 358:2240-8. doi:10.1056/NEJMoa0802315
9. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 365:2357-65. doi:10.1056/NEJMoa1108046
10. Naldini L. Ex vivo gene transfer and correction for cell-based therapies. Nat Rev Genet (2011) 12:301-15. doi:10.1038/nrg2985
11. Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet (2011) 12:341-55. doi:10.1038/nrg2988
12. Buning H. Gene therapy enters the pharma market: the short story of a long journey. EMBO Mol Med (2013) 5:1-3. doi:10.1002/emmm.201202291
13. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther (2013) 20:361-9. doi:10.1038/gt.2012.43
14. Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, Kafri T, et al. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. J Virol (2007) 81:7540-7. doi:10.1128/JVI.00529-07
15. Li H, Murphy SL, Giles-Davis W, Edmonson S, Xiang Z, Li Y, et al. Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes. Mol Ther (2007) 15:792-800. doi:10.1038/mt.sj.6300090
16. Wang L, Figueredo J, Calcedo R, Lin J, Wilson JM. Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets. Hum Gene Ther (2007) 18:185-94. doi:10.1089/hum.2007.001
17. Martino AT, Basner-Tschakarjan E, Markusic DM, Finn JD, Hinderer C, Zhou S, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood (2013) 121:2224-33. doi:10.1182/blood-2012-10-460733
18. Muzyczka N, Berns KI. Parvoviridae: The Viruses and Their Replication. Philadelphia, PA: Lippincott, Williams and Wilkins (2001).
19. Sonntag F, Schmidt K, Kleinschmidt JA. A viral assembly factor promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci U S A (2010) 107:10220-5. doi:10.1073/pnas.1001673107
20. Zhou X, Muzyczka N. In vitro packaging of adeno-associated virus DNA. J Virol (1998) 72:3241-7.
21. Atchison RW, Casto BC, Hammon WM. Adenovirus-associated defective virus particles. Science (1965) 149:754-6. doi:10.1126/science.149.3685.754
22. Arechavaleta-Velasco F, Gomez L, Ma Y, Zhao J, McGrath CM, Sammel MD, et al. Adverse reproductive outcomes in urban women with adeno-associated virus-2 infections in early pregnancy. Hum Reprod (2008) 23:29-36. doi:10.1093/humrep/dem360
23. Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW. Innate immune responses to AAV Vectors. Front Microbiol (2011) 2:194. doi:10.3389/fmicb.2011.00194
24. Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol (2013) 4:341. doi:10.3389/fimmu.2013.00341
25. Zwart MP, Hemerik L, Cory JS, de Visser JA, Bianchi FJ, Van Oers MM, et al. An experimental test of the independent action hypothesis in virus-insect pathosystems. Proc Biol Sci (2009) 276:2233-42. doi:10.1098/rspb.2009.0064
26. Jiang H, Couto LB, Patarroyo-White S, Liu T, Nagy D, Vargas JA, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood (2006) 108:3321-8. doi:10.1182/blood-2006-04-017913
27. Stieger K, Le Meur G, Lasne F, Weber M, Deschamps JY, Nivard D, et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. Mol Ther (2006) 13:967-75. doi:10.1016/j.ymthe.2006.08.510
28. Mueller C, Chulay JD, Trapnell BC, Humphries M, Carey B, Sandhaus RA, et al. Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest (2013) 123:5310-8. doi:10.1172/JCI70314
29. Ellis BL, Hirsch ML, Barker JC, Connelly JP, Steininger RJ III, Porteus MH. A survey of ex vivo/in vitro transduction efficiency of mammalian primary cells and cell lines with nine natural adeno-associated virus (AAV1-9) and one engineered adeno-associated virus serotype. Virol J (2013) 10:74. doi:10.1186/1743-422X-10-74
30. Hosel M, Broxtermann M, Janicki H, Esser K, Arzberger S, Hartmann P, et al. Toll-like receptor 2-mediated innate immune response in human nonparenchymal liver cells toward adeno-associated viral vectors. Hepatology (2012) 55:287-97. doi:10.1002/hep.24625
31. Martino AT, Suzuki M, Markusic DM, Zolotukhin I, Ryals RC, Moghimi B, et al. The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver. Blood (2011) 117:6459-68. doi:10.1182/blood-2010-10-314518
32. Zaiss AK, Cotter MJ, White LR, Clark SA, Wong NC, Holers VM, et al. Complement is an essential component of the immune response to adeno-associated virus vectors. J Virol (2008) 82:2727-40. doi:10.1128/JVI.01990-07
33. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA. Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol (2002) 76:4580-90. doi:10.1128/JVI.76.9.4580-4590.2002
34. Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest (2009) 119:2388-98. doi:10.1172/JCI37607
35. Sudres M, Cire S, Vasseur V, Brault L, Da Rocha S, Boisgerault F, et al. MyD88 signaling in B cells regulates the production of Th1-dependent antibodies to AAV. Mol Ther (2012) 20:1571-81. doi:10.1038/mt.2012.101
36. Faust SM, Bell P, Cutler BJ, Ashley SN, Zhu Y, Rabinowitz JE, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest (2013) 123:2994-3001. doi:10.1172/JCI68205
37. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, et al. Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther (2011) 19:876-85. doi:10.1038/mt.2010.274
38. Buchlis G, Podsakoff GM, Radu A, Hawk SM, Flake AW, Mingozzi F, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood (2012) 119:3038-41. doi:10.1182/blood-2011-09-382317
39. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood (2009) 113:797-806. doi:10.1182/blood-2008-10-181479
40. Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther (2001) 4:201-10. doi:10.1006/mthe.2001.0441
41. Mendell JR, Campbell K, Rodino-Klapac L, Sahenk Z, Shilling C, Lewis S, et al. Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med (2010) 363:1429-37. doi:10.1056/NEJMoa1000228
42. Wang L, Cao O, Swalm B, Dobrzynski E, Mingozzi F, Herzog RW. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther (2005) 12:1453-64. doi:10.1038/sj.gt.3302539
43. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest (2003) 111:1347-56. doi:10.1172/JCI16887
44. Rogers GL, Martino AT, Zolotukhin I, Ertl HC, Herzog RW. Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia B. J Transl Med (2014) 12:25. doi:10.1186/1479-5876-12-25
45. Arruda VR, Stedman HH, Haurigot V, Buchlis G, Baila S, Favaro P, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood (2010) 115:4678-88. doi:10.1182/blood-2009-12-261156
46. Haurigot V, Mingozzi F, Buchlis G, Hui D, Chen Y, Basner-Tschakarjan E, et al. Safety of AAV factor IX peripheral transvenular gene delivery to muscle in hemophilia B dogs. Mol Ther (2010) 18:1318-29. doi:10.1038/mt.2010.73
47. Toromanoff A, Adjali O, Larcher T, Hill M, Guigand L, Chenuaud P, et al. Lack of immunotoxicity after regional intravenous (RI) delivery of rAAV to nonhuman primate skeletal muscle. Mol Ther (2010) 18:151-60. doi:10.1038/mt.2009.251
48. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood (2003) 101:2963-72. doi:10.1182/blood-2002-10-3296
49. Stroes ES, Nierman MC, Meulenberg JJ, Franssen R, Twisk J, Henny CP, et al. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler Thromb Vasc Biol (2008) 28:2303-4. doi:10.1161/ATVBAHA.108.175620
50. Sun B, Bird A, Young SP, Kishnani PS, Chen YT, Koeberl DD. Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance. Am J Hum Genet (2007) 81:1042-9. doi:10.1086/522236
51. Zhang P, Sun B, Osada T, Rodriguiz R, Yang XY, Luo X, et al. Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum Gene Ther (2012) 23:460-72. doi:10.1089/hum.2011.063
52. Annoni A, Cantore A, Della Valle P, Goudy K, Akbarpour M, Russo F, et al. Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice. EMBO Mol Med (2013) 5:1684-97. doi:10.1002/emmm.201302857
53. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, et al. Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood (2007) 110:1132-40. doi:10.1182/blood-2007-02-073304
54. Dobrzynski E, Mingozzi F, Liu YL, Bendo E, Cao O, Wang L, et al. Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer. Blood (2004) 104:969-77. doi:10.1182/blood-2004-03-0847
55. Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood (2010) 116:5842-8. doi:10.1182/blood-2010-06-288001
56. Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA, et al. Effective gene therapy for haemophilic mice with pathogenic factor IX antibodies. EMBO Mol Med (2013) 5:1698-709. doi:10.1002/emmm.201302859
57. Martino AT, Nayak S, Hoffman BE, Cooper M, Liao G, Markusic DM, et al. Tolerance induction to cytoplasmic beta-galactosidase by hepatic AAV gene transfer: implications for antigen presentation and immunotoxicity. PLoS One (2009) 4:e6376. doi:10.1371/journal.pone.0006376
58. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood (2007) 110:2334-41. doi:10.1182/blood-2007-03-080093
59. Follenzi A, Battaglia M, Lombardo A, Annoni A, Roncarolo MG, Naldini L. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. Blood (2004) 103:3700-9. doi:10.1182/blood-2003-09-3217
60. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med (2006) 12:342-7. doi:10.1038/nm1358
61. Ferreira V, Petry H, Salmon F. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol (2014) 5:82. doi:10.3389/fimmu.2014.00082
62. Boisgerault F, Gross DA, Ferrand M, Poupiot J, Darocha S, Richard I, et al. Prolonged gene expression in muscle is achieved without active immune tolerance using microRNA 142.3p-regulated rAAV gene transfer. Hum Gene Ther (2013) 24:393-405. doi:10.1089/hum.2012.208
63. Breous E, Somanathan S, Bell P, Wilson JM. Inflammation promotes the loss of adeno-associated virus-mediated transgene expression in mouse liver. Gastroenterology (2011) 141(1):348-57, 357.e1-3. doi:10.1053/j.gastro.2011.04.002
64. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296:301-5. doi:10.1126/science.1071059
65. Mingozzi F, High KA. Immune responses to AAV in clinical trials. Curr Gene Ther (2011) 11:321-30. doi:10.2174/156652311796150354
66. Ding W, Zhang L, Yan Z, Engelhardt JF. Intracellular trafficking of adeno-associated viral vectors. Gene Ther (2005) 12:873-80. doi:10.1038/sj.gt.3302527
67. Yan Z, Zak R, Luxton GW, Ritchie TC, Bantel-Schaal U, Engelhardt JF. Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J Virol (2002) 76:2043-53. doi:10.1128/jvi.76.5.2043-2053.2002
68. Duan D, Yue Y, Yan Z, Yang J, Engelhardt JF. Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J Clin Invest (2000) 105:1573-87. doi:10.1172/JCI8317
69. Zhong L, Li B, Mah CS, Govindasamy L, Agbandje-McKenna M, Cooper M, et al. Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A (2008) 105:7827-32. doi:10.1073/pnas.0802866105
70. Pien GC, Basner-Tschakarjan E, Hui DJ, Mentlik AN, Finn JD, Hasbrouck NC, et al. Capsid antigen presentation flags human hepatocytes for destruction after transduction by adeno-associated viral vectors. J Clin Invest (2009) 119:1688-95. doi:10.1172/JCI36891
71. Finn JD, Hui D, Downey HD, Dunn D, Pien GC, Mingozzi F, et al. Proteasome inhibitors decrease AAV2 capsid derived peptide epitope presentation on MHC class I following transduction. Mol Ther (2010) 18:135-42. doi:10.1038/mt.2009.257
72. Li C, He Y, Nicolson S, Hirsch M, Weinberg MS, Zhang P, et al. Adeno-associated virus capsid antigen presentation is dependent on endosomal escape. J Clin Invest (2013) 123:1390-401. doi:10.1172/JCI66611
73. Mingozzi F, Anguela XM, Pavani G, Chen Y, Davidson RJ, Hui DJ, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med (2013) 5:194ra192. doi:10.1126/scitranslmed.3005795
74. Mingozzi F, Maus MV, Hui DJ, Sabatino DE, Murphy SL, Rasko JE, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med (2007) 13:419-22. doi:10.1038/nm1549
75. He Y, Weinberg MS, Hirsch M, Johnson MC, Tisch R, Samulski RJ, et al. Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical. Hum Gene Ther (2013) 24:545-53. doi:10.1089/hum.2013.065
76. Wu TL, Li H, Faust SM, Chi E, Zhou S, Wright F, et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. Mol Ther (2014) 22:42-51. doi:10.1038/mt.2013.218
77. Oliveira CC, van Hall T. Importance of TAP-independent processing pathways. Mol Immunol (2013) 55:113-6. doi:10.1016/j.molimm.2012.10.005
78. Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther (2012) 19:288-94. doi:10.1038/gt.2011.90
79. Erles K, Sebokova P, Schlehofer JR. Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J Med Virol (1999) 59:406-11. doi:10.1002/(SICI)1096-9071(199911)59:3406::AID-JMV223.0.CO;2-N
80. Calcedo R, Morizono H, Wang L, McCarter R, He J, Jones D, et al. Adeno-associated virus antibody profiles in newborns, children, and adolescents. Clin Vaccine Immunol (2011) 18:1586-8. doi:10.1128/CVI.05107-11
81. Hui DJ, Basner-Tschakarjan E, Chen Y, Edmonson SC, Maus MV, Podsakoff GM, et al. Characterization of AAV T cell epitopes presented by splenocytes from normal human donors. Mol Ther ASGCT Annu Meet Abstr (2012) 20(Suppl 1):S557.
82. Veron P, Leborgne C, Monteilhet V, Boutin S, Martin S, Moullier P, et al. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. J Immunol (2012) 188:6418-24. doi:10.4049/jimmunol.1200620
83. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A (2002) 99:11854-9. doi:10.1073/pnas.182412299
84. Basner-Tschakarjan E, Mingozzi F, Chen Y, Nathwani A, Tuddenham E, Riddell A, et al. Cellular immune responses to vector in a gene therapy trial for hemophilia b using an AAV8 self-complementary factor IX vector. Blood Am Soc Hematol Annu Meet (2013) 122:21.
85. Brantly ML, Chulay JD, Wang L, Mueller C, Humphries M, Spencer LT, et al. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc Natl Acad Sci U S A (2009) 106:16363-8. doi:10.1073/pnas.0904514106
86. Flotte TR, Schwiebert EM, Zeitlin PL, Carter BJ, Guggino WB. Correlation between DNA transfer and cystic fibrosis airway epithelial cell correction after recombinant adeno-associated virus serotype 2 gene therapy. Hum Gene Ther (2005) 16:921-8. doi:10.1089/hum.2005.16.921
87. Herson S, Hentati F, Rigolet A, Behin A, Romero NB, Leturcq F, et al. A phase I trial of adeno-associated virus serotype 1-gamma-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain (2012) 135:483-92. doi:10.1093/brain/awr342
88. Jaski BE, Jessup ML, Mancini DM, Cappola TP, Pauly DF, Greenberg B, et al. Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID trial), a first-in-human phase 1/2 clinical trial. J Card Fail (2009) 15:171-81. doi:10.1016/j.cardfail.2009.01.013
89. Mendell JR, Rodino-Klapac LR, Rosales XQ, Coley BD, Galloway G, Lewis S, et al. Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann Neurol (2010) 68:629-38. doi:10.1002/ana.22251
90. Mendell JR, Rodino-Klapac LR, Rosales-Quintero X, Kota J, Coley BD, Galloway G, et al. Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann Neurol (2009) 66:290-7. doi:10.1002/ana.21732
91. Mingozzi F, Meulenberg JJ, Hui DJ, Basner-Tschakarjan E, Hasbrouck NC, Edmonson SA, et al. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood (2009) 114:2077-86. doi:10.1182/blood-2008-07-167510
92. Flotte TR, Trapnell BC, Humphries M, Carey B, Calcedo R, Rouhani F, et al. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing alpha1-antitrypsin: interim results. Hum Gene Ther (2011) 22:1239-47. doi:10.1089/hum.2011.053
93. Ozeri E, Mizrahi M, Shahaf G, Lewis EC. Alpha-1 antitrypsin promotes semimature, IL-10-producing and readily migrating tolerogenic dendritic cells. J Immunol (2012) 189:146-53. doi:10.4049/jimmunol.1101340
94. Velazquez VM, Bowen DG, Walker CM. Silencing of T lymphocytes by antigen-driven programmed death in recombinant adeno-associated virus vector-mediated gene therapy. Blood (2009) 113:538-45. doi:10.1182/blood-2008-01-131375
95. Willett K, Bennett J. Immunology of AAV-mediated gene transfer in the eye. Front Immunol (2013) 4:261. doi:10.3389/fimmu.2013.00261
96. Leone P, Shera D, McPhee SW, Francis JS, Kolodny EH, Bilaniuk LT, et al. Long-term follow-up after gene therapy for Canavan disease. Sci Transl Med (2012) 4:165ra163. doi:10.1126/scitranslmed.3003454
97. McPhee SW, Janson CG, Li C, Samulski RJ, Camp AS, Francis J, et al. Immune responses to AAV in a phase I study for Canavan disease. J Gene Med (2006) 8:577-88. doi:10.1002/jgm.885
98. Worgall S, Sondhi D, Hackett NR, Kosofsky B, Kekatpure MV, Neyzi N, et al. Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum Gene Ther (2008) 19:463-74. doi:10.1089/hum.2008.022
99. Christine CW, Starr PA, Larson PS, Eberling JL, Jagust WJ, Hawkins RA, et al. Safety and tolerability of putaminal AADC gene therapy for Parkinson disease. Neurology (2009) 73:1662-9. doi:10.1212/WNL.0b013e3181c29356
100. Kaplitt MG, Feigin A, Tang C, Fitzsimons HL, Mattis P, Lawlor PA, et al. Safety and tolerability of gene therapy with an adeno-associated virus (AAV) borne GAD gene for Parkinson's disease: an open label, phase I trial. Lancet (2007) 369:2097-105. doi:10.1016/S0140-6736(07)60982-9
101. Marks WJ Jr, Bartus RT, Siffert J, Davis CS, Lozano A, Boulis N, et al. Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol (2010) 9:1164-72. doi:10.1016/S1474-4422(10)70254-4
102. Marks WJ Jr, Ostrem JL, Verhagen L, Starr PA, Larson PS, Bakay RA, et al. Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2-neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial. Lancet Neurol (2008) 7:400-8. doi:10.1016/S1474-4422(08)70065-6
103. Haurigot V, Marco S, Ribera A, Garcia M, Ruzo A, Villacampa P, et al. Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy. J Clin Invest (2013) 123(8):3254-71. doi:10.1172/JCI66778
104. Finn JD, Nichols TC, Svoronos N, Merricks EP, Bellenger DA, Zhou S, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood (2012) 120:4521-3. doi:10.1182/blood-2012-06-440123
105. Siner JI, Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M, et al. Minimal modification in the factor VIII B domain sequence ameliorates the murine hemophilia A phenotype. Blood (2013) 121:4396-403. doi:10.1182/blood-2012-10-464164
106. Cantore A, Nair N, Della Valle P, Di Matteo M, Matrai J, Sanvito F, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood (2012) 120:4517-20. doi:10.1182/blood-2012-05-432591
107. Nair N, Rincon MY, Evens H, Sarcar S, Dastidar S, Samara-Kuko E, et al. Computationally designed liver-specific transcriptional modules and hyperactive factor IX improve hepatic gene therapy. Blood (2014) 123:3195-9. doi:10.1182/blood-2013-10-534032
108. Ward NJ, Buckley SM, Waddington SN, Vandendriessche T, Chuah MK, Nathwani AC, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood (2011) 117:798-807. doi:10.1182/blood-2010-05-282707
109. McIntosh J, Lenting PJ, Rosales C, Lee D, Rabbanian S, Raj D, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood (2013) 121:3335-44. doi:10.1182/blood-2012-10-462200
110. Nathwani AC, Cochrane M, McIntosh J, Ng CY, Zhou J, Gray JT, et al. Enhancing transduction of the liver by adeno-associated viral vectors. Gene Ther (2009) 16:60-9. doi:10.1038/gt.2008.137
111. Alé A, Bruna J, Navarro X, Udina E. Neurotoxicity induced by antineoplastic proteasome inhibitors. Neurotoxicology (2014). doi:10.1016/j.neuro.2014.02.001
112. Gao K, Li M, Zhong L, Su Q, Li J, Li S, et al. Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side effects. Mol Ther Methods Clin Dev (2014) 1:9. doi:10.1038/mtm.2013.9
113. Montenegro-Miranda PS, ten Bloemendaal L, Kunne C, de Waart DR, Bosma PJ. Mycophenolate mofetil impairs transduction of single-stranded adeno-associated viral vectors. Hum Gene Ther (2011) 22:605-12. doi:10.1089/hum.2010.222
114. Unzu C, Hervas-Stubbs S, Sampedro A, Mauleon I, Mancheno U, Alfaro C, et al. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med (2012) 10:122. doi:10.1186/1479-5876-10-122
115. Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, et al. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Mol Ther (2012) 20:1501-7. doi:10.1038/mt.2012.111
116. Finn JD, Favaro P, Wright JF, Mingozzi F, High KA, Arruda VR. Rabbit anti-thymocyte globulin (rATG) administrated concomitantly with liver delivery of AAV2-hFIX can promote inhibitor formation in rhesus macaques. Blood (2010) 116:3765.
117. De Groot AS, Moise L, McMurry JA, Wambre E, Van Overtvelt L, Moingeon P, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood (2008) 112:3303-11. doi:10.1182/blood-2008-02-138073
118. Hui DJ, Basner-Tschakarjan E, Chen Y, Davidson RJ, Buchlis G, Yazicioglu M, et al. Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes. Mol Ther (2013) 21:1727-37. doi:10.1038/mt.2013.166
119. Cousens LP, Su Y, McClaine E, Li X, Terry F, Smith R, et al. Application of IgG-derived natural Treg epitopes (IgG Tregitopes) to antigen-specific tolerance induction in a murine model of type 1 diabetes. J Diabetes Res (2013) 2013:621693. doi:10.1155/2013/621693
120. van der Marel S, Majowicz A, Kwikkers K, van Logtenstein R, te Velde AA, De Groot AS, et al. Adeno-associated virus mediated delivery of Tregitope 167 ameliorates experimental colitis. World J Gastroenterol (2012) 18:4288-99. doi:10.3748/wjg.v18.i32.4288
121. Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, et al. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. Cancer Immunol Immunother (2011) 60:15-22. doi:10.1007/s00262-010-0940-z
122. Britten CM, Walter S, Janetzki S. Immunological monitoring to rationally guide AAV gene therapy. Front Immunol (2013) 4:273. doi:10.3389/fimmu.2013.00273